Women’s health medtech company ASPIVIX has recenlty joined forces with Bayer Switzerland to introduce Carevix, a cervical stabilizer designed to minimize pain and bleeding during transcervical procedures, including IUD placement. This collaboration combines Bayer’s extensive expertise in contraceptive solutions with ASPIVIX’s dedication to modernizing gynecology. Their shared objective is to improve the gynecological experience for women, particularly by addressing the discomfort often associated with IUD procedures.
The conventional use of the century-old cervical tenaculum in gynecological procedures has frequently resulted in pain during IUD insertion, affecting millions of women globally. Carevix offers a viable alternative, utilizing suction technology to stabilize the cervix. Clinical trials have demonstrated its efficacy in reducing both pain and bleeding, addressing a significant unmet need in women’s healthcare.
ASPIVIX CEO, Mathieu Horras, commented: “ASPIVIX is excited to enter this partnership with Bayer (Schweiz) AG that truly emphasize the goal of empowering women to select the best contraceptive solution without worrying about potential pain and bleeding. The thorough research and clinical data behind Carevix guarantee a notable decrease in pain and bleeding, enhancing the experience of IUD adoption and placement, as well as various other gynecological procedures for millions of women.”
Bayer Switzerland Women’s Healthcare lead, Marco Gierten, added: “As a globally trusted brand,
Bayer remains committed to advancing solutions that provide significant benefits to patients.”
Aspivix received CE Mark approval in December 2023, further validating its efficacy and safety for use in gynecological procedures.
